Zogenix Inc (NASDAQ:ZGNX) Sellers Strengthened Their Shorts By 1.5%

June 29, 2018 - By Estela Ashley

Zogenix, Inc. (NASDAQ:ZGNX) Corporate Logo

Zogenix Inc (NASDAQ:ZGNX) had an increase of its short interest by 1.5%. In June was announced ZGNX’s total 4.37M short interest by FINRA. The up change of 1.5% from 4.31M shares was reported. Former ZGNX’s position will need 10 days to recover. It has 461,100 average volume. Zogenix Inc’s short interest float is 15.63%.

ZGNX hit $44.1 during the last trading session after $0.85 change.Zogenix, Inc. has volume of 402,807 shares. Since June 29, 2017 ZGNX has risen 225.58% and is uptrending. ZGNX outperformed by 213.01% the S&P 500.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States.The company has $1.55 billion market cap. The companyÂ’s lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.Currently it has negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

There’s a substantial Zogenix, Inc. (NASDAQ:ZGNX) news announced by Investorplace.com. It’s an article titled: “Here’s the Reason that GWPH Stock Tumbled Despite Regulatory Victory” on June 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.